Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in: Journal of Neurology 12/2015

01-12-2015 | Original Communication

Rituximab is effective in severe treatment-resistant neurological Behçet’s syndrome

Author: D. P. Kidd

Published in: Journal of Neurology | Issue 12/2015

Login to get access

Abstract

The objective of this study is to describe a case of severe and treatment-resistant neurological Behçet’s syndrome responsive to a novel therapy. This case report describes the patient who failed to respond to conventional therapy but the brain stem lesion resolved with the anti-CD20 biological agent rituximab. Neurological complications are uncommon in Behçet’s syndrome; 80 % involve a meningoencephalitis which can be severe and relapsing. This is the first report of effectiveness of rituximab in this uncommon disease.
Literature
1.
Yazici H, Fresko I, Yurdakul S (2007) Behçet’s syndrome: disease manifestations, management and advances in treatment. Nat Clin Pract Neurol 3:148–155CrossRef
2.
Al Araji A, Kidd D (2009) Neuro-Behçet’s disease: epidemiology, clinical characteristics and management. Lancet Neurol 8:192–204CrossRefPubMed
3.
Atida A, Fragiadaki K, Giavri E, Sfikakis PP (2011) Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 4:61–70
4.
Pipitone N, Olivieri I, Padula A et al (2008) Infliximab for the treatment of Neuro-Behçet’s disease: a case series and review of the literature. Arthritis Rheum 59:285–290CrossRefPubMed
5.
Sadreneddini S, Noshad H, Molaeefard M, Noshad R (2008) Treatment of retinal vasculitis in Behçet’s disease with Rituximab. Mod Rheumatol 18:306–308CrossRef
6.
Caso F, Costa L, Rigante D et al (2014) Biological treatments in Behçet’s disease: beyond anti-TNF therapy. Med Inflamm 2014:107421CrossRef
Metadata
Title
Rituximab is effective in severe treatment-resistant neurological Behçet’s syndrome
Author
D. P. Kidd
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 12/2015
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-7897-y

Other articles of this Issue 12/2015

Journal of Neurology 12/2015 Go to the issue

Erratum

Erratum to: Caregiver burden in amyotrophic lateral sclerosis: a cross-sectional investigation of predictors

Letter to the Editors

Parkinsonism–hyperpyrexia syndrome and deep brain stimulation

Original Communication

Powerhouse failure and oxidative damage in autosomal recessive spastic ataxia of Charlevoix-Saguenay

Original Communication

Site and size of multiple sclerosis lesions predict enhanced or decreased female orgasmic function

Pioneers in Neurology

William John Adie (1886–1935)

Original Communication

Long-term effect on dystonia after pallidal deep brain stimulation (DBS) in three members of a family with a THAP1 mutation